SolAeroMed is the leader in biophysical
respiratory drugs and delivery devices.

Learn More

S-1226™

Asthma Rescue Drug & Delivery Device
In Phase II Clinical Trials

S-1229™

Surfactant Dysfunction
In Pre-Clinical Development

Sleep Apnea Device

Treats apneas
In Pre-Clinical Development

About SolAeroMed

SolAeroMed is a company dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases. Our lead asthma drug, S-1226, is in Phase II clinical trials designed to demonstrate Proof of Concept.

Events

SolAeroMed management and clinicians have a number of upcoming conferences it will be attending. Please visit our News & Events page for more details.

SolAeroMed is seeking development partners for their
novel Asthma, Surfactant Dysfunction, and Sleep Apnea products.

Learn More

top